These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

229 related items for PubMed ID: 11851753

  • 1. Total thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and pro-TAFI in patients with haemophilia A.
    Antovic J, Schulman S, Eelde A, Blombäck M.
    Haemophilia; 2001 Nov; 7(6):557-60. PubMed ID: 11851753
    [Abstract] [Full Text] [Related]

  • 2. Thrombin-activatable fibrinolysis inhibitor antigen and TAFI activity in patients with APC resistance caused by factor V Leiden mutation.
    Antovic JP, Blombäck M.
    Thromb Res; 2002 Apr 01; 106(1):59-62. PubMed ID: 12165290
    [Abstract] [Full Text] [Related]

  • 3. Does an enzyme other than thrombin contribute to unexpected changes in the levels of the different forms of thrombin activatable fibrinolysis inhibitor in patients with hemophilia A, hemophilia B and von Willebrand disease?
    Antovic JP, Schulman S, An SS, Greenfield RS, Blombäck M.
    Scand J Clin Lab Invest; 2004 Apr 01; 64(8):745-51. PubMed ID: 15719893
    [Abstract] [Full Text] [Related]

  • 4. On-demand but not prophylactic treatment with FVIII concentrate increase thrombin activatable fibrinolysis inhibitor activation in severe haemophilia A patients.
    Mikovic D, Woodhams BJ, Holmström M, Elezovic I, Antovic A, Mobarrez F, Elfvinge P, Antovic JP.
    Int J Lab Hematol; 2012 Feb 01; 34(1):35-40. PubMed ID: 21707936
    [Abstract] [Full Text] [Related]

  • 5. Thrombin activatable fibrinolysis inhibitor (TAFI): a molecular link between coagulation and fibrinolysis.
    Miljić P, Heylen E, Willemse J, Djordjević V, Radojković D, Colović M, Elezović I, Hendriks D.
    Srp Arh Celok Lek; 2010 Jan 01; 138 Suppl 1():74-8. PubMed ID: 20229688
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Thrombin activatable fibrinolysis inhibitor and hemostatic changes in patients with type I diabetes mellitus with and without microvascular complications.
    Antovic JP, Yngen M, Ostenson CG, Antovic A, Wallen HN, Jorneskög G, Blombäck M.
    Blood Coagul Fibrinolysis; 2003 Sep 01; 14(6):551-6. PubMed ID: 12960608
    [Abstract] [Full Text] [Related]

  • 8. Overall haemostatic potential can be used for estimation of thrombin-activatable fibrinolysis inhibitor-dependent fibrinolysis in vivo and for possible follow-up of recombinant factor VIIa treatment in patients with inhibitors to factor VIII.
    Antovic JP, Antovic A, He S, Tengborn L, Blombäck M.
    Haemophilia; 2002 Nov 01; 8(6):781-6. PubMed ID: 12410647
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U).
    Bouma BN, Meijers JC.
    J Thromb Haemost; 2003 Jul 01; 1(7):1566-74. PubMed ID: 12871292
    [Abstract] [Full Text] [Related]

  • 11. [Thrombin activatable fibrinolysis inhibitor (TAFI) and its importance in the regulation of fibrinolysis].
    Stasko J, Hudecek J, Kubisz P.
    Vnitr Lek; 2004 Jan 01; 50(1):36-44. PubMed ID: 15015228
    [Abstract] [Full Text] [Related]

  • 12. Thrombin-activatable fibrinolysis inhibitor.
    Marx PF.
    Curr Med Chem; 2004 Sep 01; 11(17):2335-48. PubMed ID: 15379716
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Thrombin activatable fibrinolysis inhibitor (TAFI): a role in pre-eclampsia?
    Dusse LM, Cooper AJ, Lwaleed BA.
    Clin Chim Acta; 2007 Mar 01; 378(1-2):1-6. PubMed ID: 17184758
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex.
    Bajzar L, Morser J, Nesheim M.
    J Biol Chem; 1996 Jul 12; 271(28):16603-8. PubMed ID: 8663147
    [Abstract] [Full Text] [Related]

  • 18. Reduced fibrinolytic resistance in patients with factor XI deficiency. Evidence of a thrombin-independent impairment of the thrombin-activatable fibrinolysis inhibitor pathway.
    Colucci M, Incampo F, Cannavò A, Menegatti M, Siboni SM, Zaccaria F, Semeraro N, Peyvandi F.
    J Thromb Haemost; 2016 Aug 12; 14(8):1603-14. PubMed ID: 27094709
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Proteolytic activation of purified human procarboxypeptidase U.
    Schatteman KA, Goossens FJ, Scharpé SS, Hendriks DF.
    Clin Chim Acta; 2000 Feb 25; 292(1-2):25-40. PubMed ID: 10686274
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.